- Home
- UPXI vs KLRS Comparison
UPXI vs KLRS Comparison
Compare UPXI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | KLRS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 46.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UPXI | KLRS |
|---|---|---|
| Price | $0.72 | $8.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 4.0M | 52.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $141.57 | N/A |
| Revenue Next Year | $14.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.14 |
| 52 Week High | $22.57 | $12.90 |
Technical Indicators
Market Signals| Indicator | UPXI | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 20.89 | 42.30 |
| Support Level | $0.71 | $8.25 |
| Resistance Level | $2.05 | $10.28 |
| Average True Range (ATR) | 0.14 | 0.87 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 1.09 | 5.00 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.